Acquisitions |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Combination [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Acquisitions | ACQUISITIONS We acquire stock in companies and various assets that continue to support our capital deployment and product development strategies. In the six months 2026 and 2025 cash paid for acquisitions, net of cash acquired was $459 and $4,814. In May 2026 we completed the acquisition of AVS for net cash consideration of $435 and up to $400 in future milestone payments that had a fair value of $271 at the acquisition date. AVS is developing a next-generation intravascular lithotripsy platform designed to treat complex peripheral arterial disease. AVS is part of our Peripheral Vascular business within MedSurg and Neurotechnology. Acquired in-process research and development intangible assets represent projects where the related product has not yet received regulatory approval. The purchase price allocation for AVS is based on preliminary valuations, primarily related to in-process research and development. Goodwill attributable to the acquisition reflects the strategic benefits of expanding our peripheral vascular portfolio. This goodwill is not deductible for tax purposes. In February 2025 we completed the acquisition of Inari for $80 per share, or an aggregate purchase price of $4,810, net of cash acquired. Inari's product portfolio includes minimally invasive products for the treatment of venous thromboembolism. Inari is part of our Peripheral Vascular business within MedSurg and Neurotechnology. Goodwill attributable to the acquisition reflects the strategic benefits of expanding our market presence, diversifying our product portfolio and advancing innovations. This goodwill is not deductible for tax purposes. Share-based awards for Inari employees vested upon our acquisition and a charge of $139 was recorded in selling, general and administrative expenses in the six months 2025. The purchase price allocations for AVS and Inari are:
Consolidated estimated annual amortization expense for definite- lived intangible assets is:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||